FindTrial
Sign In

Analysis of the efficacy and safety of methotrexate and mifepristone in conservative treatment of ectopic pregnancy

Analysis of the efficacy and safety of methotrexate and mifepristone in conservative treatment of ectopic pregnancy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105459
Enrollment
Unknown
Registered
2025-07-03
Start date
2025-07-03
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ectopic pregnancy

Interventions

RU-486+MTX Group:None
MTX Group:None
RU-486 Group:None
MTX+RU-486 Group:None

Sponsors

Wuxi Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1: Patients diagnosed with ectopic pregnancy: based on the patient's medical history, blood biochemical indicators, and ultrasound diagnosis; 2: Vital signs are stable; 3: Blood ß - HCG<5000mIU/ml; 4: Ectopic pregnancy mass = 4cm.

Exclusion criteria

Exclusion criteria: 1: Patients with ruptured gestational mass and unstable vital signs; 2: There are contraindications for drug therapy; 3: B-ultrasound indicates the presence of embryonic heart outside the uterus; 4: Those with poor compliance and unable to follow up regularly.

Design outcomes

Primary

MeasureTime frame
human chorionic gonadotropin, HCG;—

Secondary

MeasureTime frame
progesterone;—

Countries

China

Contacts

Public ContactJilai Xie

Wuxi Maternal and Child Health Hospital

xiejilai@163.com+86 157 9626 6947

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026